News
Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...
Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...
13hon MSN
Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...
The stock's fall snapped a two-day winning streak.
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...
Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...
Lynozyfic’s global sales are projected to reach $707 million by 2031.
DNA data saved: 23andMe co-founder Anne Wojcicki has bid $305 million through a nonprofit to acquire her bankrupt company, ...
Former CEO Anne Wojcicki has prevailed in the bankruptcy auction of 23andMe, its consumer and biopharma research businesses, ...
5don MSN
Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...
TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...
Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results